RNA Avidity Biosciences: Price-to-Projected Revenue Ratio
Avidity Biosciences (RNA) is expanding its RNA therapy trial program to combat muscular dystrophies. Innovations in drug delivery and the probability of deals with industry behemoths are driving growth. However, financial stability remains fragile due to dependence on regulatory verdicts. The forward P/S based on forecasts demonstrates the impact of interest rates on share prices, where the value 585.30 shows the current magnitude of this indicator.
RNA (Avidity Corp): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Capital Avidity Biosciences|RNA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Avidity Biosciences|RNA - Company Aggregate Debt|Debts to Book Capitalization Avidity Corp|RNA - Company Long-Term Liabilities|Company Short-Term Debts Avidity Biosciences|Quick Liquidity aviditybiosciences.com
- financial results and valuation multiples details:
RNA - Net Financial Result|Expected Profit Avidity Biosciences|RNA - Company Value to Net Income|Future Price to Earnings Avidity|RNA - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Avidity Corp|RNA - Operating profit EBITDA|Net earnings per share (EPS TTM) Avidity Biosciences|RNA - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months aviditybiosciences.com|RNA - Earnings per share growth this year|Earnings growth forecast for next year Avidity Biosciences
- sales and revenue data:
Fundamental company valuation:Avidity Biosciences, Inc. RNA
To find a balance between asset quality and cost, an investor analyzes market capitalization dynamics relative to projected sales volumes, which allows for an assessment of the premium for future growth. In the case of Avidity Biosciences (RNA), which has no current sales, the expected market cap-to-revenue ratio reflects the speculative value of the RNA drug platform and market optimism ahead of the publication of final clinical trial data.
Competitors of Avidity Biosciences (RNA)
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Qiagen NV (QGEN) - Market Cap to Future Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Repligen Inc. RGEN|CRSP: Forward P/S Multiple|Forward Price-to-Revenue Multiple genedx.com|RARE (Ultragenyx) - Forward P/S Multiple|Beam Therapeutics Inc (BEAM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple SRPT|TWST - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio 10x Genomics, Inc. TXG|NTLA: Market Cap to Projected Revenue|Stoke Therapeutics, Inc. - Forward P/S Multiple|BioLife Solutions Inc (BLFS) - Forward Price-to-Revenue Multiple|WVE: Forward P/S Multiple|Market Cap to Future Revenue Ratio Maze Therapeutics Corp (MAZE)|Price-to-Projected Revenue Ratio Sionna Therapeutics Inc|primemedicine.com (PRME) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|QURE (uniQure NV) - Forward Price to Sales|Price-to-Projected Revenue Ratio MeiraGTx PLC MGTX|RGNX: Market Cap to Projected Revenue|Solid Biosciences Inc. - Forward P/S Multiple|OCGN - Forward P/S Multiple|PACB: Forward P/S Multiple|Market Cap to Projected Revenue BNTC|Price-to-Projected Revenue Ratio Design Pharma|Market Cap to Projected Revenue RCKT (Rocket Corp)|Forward P/S Multiple FDMT|Forward P/S Multiple lexeotx.com (LXEO)|Forward P/S Multiple KRRO (Korro Bio)|Forward P/S Multiple Editas Medicine Inc EDIT|SLN: Forward Price-to-Revenue Multiple|PRQR: Price-to-Projected Revenue Ratio|CDXS: Forward P/S Multiple|SGMO - Market Cap to Expected Sales Ratio|NAUT (Nautilus Biotechnology, Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue MGX (Metagenomi Inc.)|Forward P/S Multiple DTIL|Market Cap to Expected Sales Ratio generationbio.com|Boundless Bio, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio XCUR (Exicure Inc.)|IMNN: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Phio Pharmaceuticals|MBIO (mustangbio.com) - Forward Price-to-Revenue Multiple|TransCode Therapeutics, Inc. - Forward Price to Sales|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio APDN|Forward P/S Multiple BLUE|Market Cap to Expected Sales Ratio immunoprecise.com|Price-to-Projected Revenue Ratio Omega OMGA|Singular Genomics Corp (OMIC) - Market Cap to Future Revenue Ratio|RGLS - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio syros.com SYRS|TBIO: Forward P/S Multiple|Forward Price-to-Revenue Multiple TRACON Pharmaceuticals Inc.|UBX (Unity Bio) - Forward P/S Multiple
